A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, allows for calcineurin-inhibitor free immunosuppressive therapy in kidney transplantation but is associated with a higher acute rejection risk than ciclosporin. Thus far, no biomarker for belatacept-resistant rejection has been validated. In this randomized-controlled trial, acute rejection rate was compared between belatacept- and tacrolimus-treated patients and immunological biomarkers for acute rejection were investigated.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Transplantation

Title: Transplantation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1534-6080

ISSN (Print): 0041-1337

Publication date (Electronic): October 2017

Volume: 101

Issue: 10

Affiliations

[1 ] 1 Division of Nephrology and Kidney Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. 2 Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. 3 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. 4 Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Article

DOI: 10.1097/TP.0000000000001755

PubMed ID: 28403127

SO-VID: 6add0bde-5d9a-4671-9b48-b80de9889967

History

Data availability:

Comments

Comment on this article

scite_

Cited by 18

See all cited by